8-K: Charlotte's Web Co-Founder Jared Stanley Resigns from Board

Co-founder Jared Stanley has resigned from the Charlotte's Web Board of Directors to focus on his role as CEO of clinical-stage pharmaceutical venture DeFloria, Inc.

Summary

• Jared Stanley resigned from the Board of Directors of Charlotte's Web Holdings, Inc. effective June 3, 2026.
• The resignation is amicable and not due to any disagreements regarding company operations, policies, or financial disclosures.
• Mr. Stanley will continue to serve the company in an advisory capacity, specifically regarding cultivation and regulatory matters.
• The departure allows Mr. Stanley to dedicate full attention to his role as CEO of DeFloria, Inc., a clinical-stage botanical pharmaceutical company co-founded by Charlotte's Web.
• Following the resignation, the Board of Directors will consist of six members.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral corporate governance event; while the loss of a co-founder is notable, the transition is orderly and maintains strategic continuity through an advisory role.

Positives

• The transition is described as amicable, with continued alignment between the company and the departing director.
• Mr. Stanley will remain involved in an advisory capacity, ensuring continuity in key areas like cultivation and regulatory strategy.
• The move strengthens the leadership focus on DeFloria, a strategic venture in which Charlotte's Web holds a stake and shares proprietary hemp genetics.
• The company maintains its connection to the ONE HEMP coalition through Mr. Stanley's continued participation.

Negatives

• Loss of a co-founder from the Board of Directors may be perceived as a reduction in direct oversight from the founding family.
• The Board size is reduced to six members, which may concentrate influence among remaining directors.

Risks

• Potential for future strategic misalignment if the interests of DeFloria and Charlotte's Web diverge.
• Reliance on the success of the AJA001 clinical trial, which is subject to FDA regulatory hurdles and pharmaceutical development risks.
• General market risks associated with the hemp and CBD industry, including evolving federal regulations and competitive pressures.
• Dependence on the availability of capital to fund ongoing operations and clinical research.

Future Outlook

The company expects to continue its partnership with DeFloria as it advances the AJA001 oral solution through FDA Phase 2 clinical trials, leveraging Charlotte's Web's proprietary hemp genetics.

Management Comments

• On behalf of the entire Board and management team, we thank Jared for his vision and his many contributions as a founder of Charlotte's Web.
• Stepping back from the Board allows me to put my full energy into DeFloria at a pivotal moment, as we advance AJA001 through Phase 2 and federal policy increasingly recognizes the therapeutic potential of cannabinoids.

Industry Context

StockSavvy.ai notes that this transition reflects a broader trend in the cannabis and hemp sector where companies are increasingly spinning off or separating clinical-stage pharmaceutical research from consumer-facing wellness brands to better manage regulatory and capital requirements.

Comparison to Industry Standards

• The separation of clinical-stage drug development from consumer wellness operations is a standard practice for companies like GW Pharmaceuticals (now part of Jazz Pharmaceuticals) to isolate regulatory risk.
• The move aligns with industry trends of professionalizing boards as companies transition from founder-led startups to more mature, regulated entities.

Management Changes

Corporate Governance

Related Party Transactions

• Charlotte's Web is a co-founder and shareholder of DeFloria, Inc., and provides proprietary hemp genetics for its clinical research.

Stakeholder Impact

• Shareholders may view the continued advisory role as a positive sign of stability.
• The focus on DeFloria may offer long-term upside potential for shareholders if the clinical-stage drug development succeeds.

Next Steps

• Continued advancement of the AJA001 clinical trial by DeFloria.
• Ongoing advisory support from Jared Stanley to Charlotte's Web.

Key Dates

Recommendation

The resignation is a standard corporate governance event and does not fundamentally alter the company's financial position or core business strategy, warranting a hold position until further operational or clinical milestones are reached.

Keywords

Charlotte's Web, CWEB, Jared Stanley, DeFloria, CBD, Hemp, Board Resignation, Botanical Pharmaceuticals